Skip to content

Muscle Relaxation Therapy With Odorant Cue

A Study of Enhancement of Progressive Muscle Relaxation Therapy for Generalized Anxiety Disorder Through Use Of An Odorant Cue.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00208910
Enrollment
15
Registered
2005-09-21
Start date
2003-11-30
Completion date
2005-05-31
Last updated
2013-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Generalized Anxiety Disorder

Keywords

Anxiety, Mental Health

Brief summary

A novel procedure for generalized anxiety disorder where an odorant cue is paired with the state of deep relaxation during training. It is hypothesized that by smelling the odor in an anxiety-provoking situation, the patient will more easily invoke a state of relaxation, providing greater relief from the distressing tension and worry that characterize GAD.

Detailed description

We hypothesize that by presenting a novel odor to a patient in a state of deep relaxation, the odor will serve as a conditioned inhibitory stimulus, or safety signal, in anxiety-provoking situations. With the odor serving as a contextual cue for the state of relaxation.

Interventions

BEHAVIORALOdorant Cue

Sponsors

Emory University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* GAD without a comorbid active major psychiatric disorder. * GAD must be the primary active psychiatric disorder. * GAD determined via the Mini International Neuropsychiatric Interview (MINI).

Exclusion criteria

* Significant medical illness that might interfere with the relaxation therapy or with training using the odorant. * Actively abusing alcohol. * Illicit substances. * Currently using rapid-acting anxiolytic agents (e.g. benzodiazepines, hydroxyzine). * Started an antidepressant, antipsychotic or mood stabilizing agent within three months of screening visit.

Design outcomes

Primary

MeasureTime frame
PSWQ

Secondary

MeasureTime frame
HAM-A

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026